These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16908524)

  • 1. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
    Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
    J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
    Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
    Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
    Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
    J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
    Bekes EM; Deryugina EI; Kupriyanova TA; Zajac E; Botkjaer KA; Andreasen PA; Quigley JP
    Neoplasia; 2011 Sep; 13(9):806-21. PubMed ID: 21969814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase.
    Kilpatrick LM; Harris RL; Owen KA; Bass R; Ghorayeb C; Bar-Or A; Ellis V
    Blood; 2006 Oct; 108(8):2616-23. PubMed ID: 16794252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
    Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
    FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
    Suzuki M; Kobayashi H; Kanayama N; Saga Y; Suzuki M; Lin CY; Dickson RB; Terao T
    J Biol Chem; 2004 Apr; 279(15):14899-908. PubMed ID: 14747469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
    Meissauer A; Kramer MD; Schirrmacher V; Brunner G
    Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22.
    Yasuda S; Morokawa N; Wong GW; Rossi A; Madhusudhan MS; Sali A; Askew YS; Adachi R; Silverman GA; Krilis SA; Stevens RL
    Blood; 2005 May; 105(10):3893-901. PubMed ID: 15701722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles and regulation of membrane-associated serine proteases.
    Qiu D; Owen K; Gray K; Bass R; Ellis V
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):583-7. PubMed ID: 17511657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
    Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
    Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
    Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
    Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.